Clinical significance of a transient increase in carcinoembryonic antigen and carbohydrate antigen19-9 in patients with metastatic colorectal cancer receiving chemotherapy

Chinese Journal of Cancer

Volumn 28, Issue 9, 2009, Pages

  Li, Yu Hong ^a   An, Xin ^a   Xiang, Xiao Juan ^a   Wang, Zhi Qiang ^a   Wang, Feng Hua ^a   Feng, Fen ^a   Jiang, Wen Qi ^a   He, You Jian ^a   Xu, Rui Hua ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

CA199; CEA surge; Chemotherapy; Efficacy; Metastatic colorectal cancer (MCRC)

Indexed keywords

CA 19-9 ANTIGEN; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADOLESCENT; ADULT; AGED; ANTIGEN FUNCTION; ARTICLE; CANCER CHEMOTHERAPY; CHILD; CHINESE; COLORECTAL CANCER; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MONOTHERAPY; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; SCHOOL CHILD; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 77951676225     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.009.10001     Document Type: Article

References (22)

1. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab in combination with irinotecan plus fluorouracil plus leucovorin chemotherapy prolongs survival but increases adverse events in people with metastatic colorectal cancer [J]. Cancer Treat Rev, 2004, 30: 715-717.
2. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J]. N Engl J Med, 2004, 351(4): 337-345.
3. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study [J]. J Clin Oncol, 2004, 22(2):229-237.
4. Grothey A. A comparison of XELOX with FOLFOX-4 as first-line treatment for metastatic colorectal cancer [J]. Nat Clin Pract Oncol, 2009, 6(1): 10-11.
5. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology [J]. J Clin Oncol, 1996, 14(10):2843-2877.
6. Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer [J]. J Clin Oncol, 2006, 24(33): 5313-5327.
7. Sorbye H, Dahl O. Transient CEA increase at start of oxaliplatin combination therapy for metastatic colorectal cancer [J], Acta Oncol, 2004, 43(5): 495-498.
8. Ailawadhi S, Sunga A, Rajput A, et al. Chemotherapy-induced carcinoembryonic antigen surge in patients with metastatic colorectal cancer [J]. Oncology, 2006, 70(1): 49-53.
9. Wanebo HJ, Rao B, Pinsky CM, et al. Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer [J]. N Engl J Med, 1978, 299(9): 448-451.
10. Fletcher RH. Carcinoembryonic antigen [J]. Ann Intern Med, 1986, 104(1):66-73.
11. Sturgeon C. Practice guidelines for tumor marker use in the clinic [J]. Clin Chem, 2002, 48(8): 1151-1159.
12. Sturgeon CM, Hoffman BR, Chan DW, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements [J]. Clin Chem, 2008, 54(8): e1-e10.
13. Tumour markers in gastrointestinal cancers-EGTM recommendations. European Group on Tumour Markers [J]. Anticancer Res, 1999, 19(4A): 2811-2815.
14. Horwich A, Peckham MJ. Transient tumor marker elevation following chemotherapy for germ cell tumors of the testis [J]. Cancer Treat Rep, 1986, 70(11): 1329-1331.
15. Loprinzi CL, Tormey DC, Rasmussen P, et al. Prospective evaluation of carcinoembryonic antigen levels and alternating chemotherapeutic regimens in metastatic breast cancer [J]. J Clin Oncol, 1986, 4(1): 46-56.
16. Kim HJ, Lee KW, Kim YJ, et al. Chemotherapy-induced transient CEA and CA19-9 surges in patients with metastatic or recurrent gastric cancer [J]. Acta Oncol, 2009, 48(3):385-390.
17. Ohtsukasa S, Okabe S, Yamashita H, et al. Increased expression of CEA and MHC class I in colorectal cancer cell lines exposed to chemotherapy drugs [J]. J Cancer Res Clin Oncol, 2003, 129(12): 719-726.
18. Aquino A, Formica V, Prete SP, et al. Drug-induced increase of carcinoembryonic antigen expression in cancer cells [J]. Pharmacol Res, 2004, 49(5): 383-396.
19. Toth CA, Thomas P. The effect of interferon treatment on 14 human colorectal cancer cell lines: growth and carcinoembryonic antigen secretion in vitro [J]. J Interferon Res, 1990, 10(6): 579-588.
20. Moertel CG, Fleming TR, Macdonald JS, et al. An evaluation of the carcinoembryonic antigen(CEA) test for monitoring patients with resected colon cancer [J]. JAMA, 1993, 270(8): 943-947.
21. von Kleist S. The clinical value of the tumor markers CA 19/9 and carcinoembryonic antigen(CEA) in colorectal carcinomas: a critical comparison [J]. Int J Biol Markers, 1986, 1(1): 3-8.
22. Grotowski M. [Antigens(CEA and CA 19-9) in diagnosis and prognosis colorectal cancer] [J]. Pol Merkur Lekarski, 2002, 12(67): 77-80.